Feeba P
- Lecturer, Rajiv Gandhi university of health science & Indian nursing council, Karnataka, India
Abstract
Marchiafava-Bignami syndrome (MBS) is a rare neurological disorder characterized by demyelination and necrosis of the corpus callosum, which is the main bundle of nerve fibers connecting the two hemispheres of the brain. MBS primarily affects individuals with chronic alcoholism, although cases unrelated to alcohol consumption have also been reported. The corpus callosum is affected in almost a pathognomonic way. The clinical presentation is based on neurological impairment, motor abnormalities, seizures, behavioral changes, and, in severe cases, coma. The diagnosis of MBS involves a combination of clinical assessment, neurological examinations, neuroimaging studies (such as magnetic resonance imaging), and, in some cases, biopsy can be done to assess necrosis, degeneration and gliosis. Management of MBS focuses on addressing underlying causes, providing supportive care, and managing symptoms. This includes alcohol cessation, nutritional support, seizure management, symptomatic treatment, rehabilitation therapies, and psychosocial support. However, the prognosis for MBS is generally poor, with a high mortality rate. Collaboration with the healthcare team and ensuring continuity of care are essential for providing comprehensive and coordinated nursing care for individuals with MBS.
Keywords: Corpus callosum, hemisphere, demyelination, gliosis, syndrome
[This article belongs to Research & Reviews: A Journal of Neuroscience(rrjons)]
References
- Hillbom M, Saloheimo P, Fujioka S, Wszolek ZK, Juvela S, Leone MA. Diagnosis and management of Marchiafava–Bignami disease: a review of CT/MRI confirmed cases. J Neurol Neurosurg 2014 Feb 1; 85(2): 168–73.
- Tian TY, Pescador Ruschel MA, Park S, et al. Marchiafava-Bignami Disease. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK526007/
- Paulo Eduardo Mestrinelli Carrilho, Marcius Benigno Marques dos Santos, Larisa Piasecki, Amaury Cezar Jorge. Marchiafava-Bignami disease: a rare entity with a poor outcome. Rev Bras Ter Intensiva. 2013 Jan-Mar; 25(1): 68–72.
- Zhang YL, Ran C, Xu C, Li W. Clinico-radiologic subtypes and therapeutic observation of acute Marchiafava-Bignami disease. Sci Rep. 2023 Oct 28; 13(1):
- Hillbom M, Saloheimo P, Fujioka S, Wszolek ZK, Juvela S, Leone MA. Diagnosis and management of Marchiafava–Bignami disease: a review of CT/MRI confirmed cases. J Neurol Neurosurg 2014 Feb 1; 85(2): 168–73.
- Kumar S, Challam R, Naveen J, Singh WJ. Marchiafava-bignami disease: a case report. J Clin Diagn Res (JCDR). 2014 Aug; 8(8): RD01–2.
- Parmanand H Marchiafava-Bignami disease in chronic alcoholic patient. Radiol Case Rep. 2016 Jul 9; 11(3): 234–7.
- Lurlaro S, Crosio C, D’Aprile C, Marini S, Vaccaro R, Fasulo Marchiafava-Bignami Disease: From Diagnosis to Treatment. Neurol Sci. 2019; 40(3): 461–6.
- Dong Xiaoyu (PhD), Bai Chaobo (MD), Nao Jianfei (PhD). Clinical and radiological features of Marchiafava–Bignami disease. Medicine. 2018 Feb; 97(5): e9626.
- Sechi G, Serra A. Wernicke’s encephalopathy: new clinical settings and recent advances in diagnosis and management. Lancet Neurol. 2007 May; 6(5): 442–
- Matsuura Hiroki, Katsuro Shindo. Marchiafava–Bignami disease. QJM: Int J 2018; 111(10): 755–755.
- Kinno R, Yamamoto M, Yamazaki T, et al. Cerebral Microhemorrhage in MarchiafavaBignami Disease Detected by Susceptibility-Weighted Imaging. Neurol Sci. 2013; 34(4): 545–8.
- Tung CS, Wu SL, Tsou JC, Hsu SP, Kuo HC, Tsui HW. Marchiafava-Bignami disease with widespread lesions and complete recovery. Am J Neuroradiol. 2010 Sep 1; 31(8): 1506–
Research & Reviews: A Journal of Neuroscience
| Volume | 14 |
| Issue | 01 |
| Received | February 19, 2024 |
| Accepted | February 22, 2024 |
| Published | April 19, 2024 |